<DOC>
	<DOC>NCT01443364</DOC>
	<brief_summary>The study aims to evaluate the predictability of early response to Certolizumab pegol in combination with Methotrexate at one year in patients with moderate to severe rheumatoid arthritis.</brief_summary>
	<brief_title>Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>diagnosis of adultonset Rheumatoid Arthritis (RA) for a duration of at least 6 months but not longer than 5 years positive Rheumatoid Factor (RF) and/or positive anti Cyclic Citrullinated Peptide (antiCCP) active RA disease subjects must have failed at least one traditional Disease Modifying AntiRheumatic Drug (DMARD). subject is na√Øve to RA related biologics a diagnosis of any other inflammatory arthritis history of infected joint prosthesis, or other significant infection known Tuberculosis (TB) disease or high risk of acquiring TB infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Certolizumab pegol - Cimzia</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Power Doppler Ultrasonography</keyword>
	<keyword>Italy</keyword>
	<keyword>Moderate-severe Rheumatoid Arthritis</keyword>
</DOC>